Anubhab Mukherjee
Esperer Onco Nutrition, Aavishkar Oral Strip Pvt Ltd, Indian Institute of Chemical Technology, John Wayne Cancer Institute
Research areas: Materials Science · Biomaterials · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses
0000-0002-3082-8269
About
A former member of Laboratory of Nanomedicine, Brigham and Women’s Hospital, Harvard University, Boston, USA, Dr. Anubhab Mukherjee is an ardent votary of science who strives to make an impact in the lives of those afflicted with cancer and other chronic/acute ailments. He completed his Ph.D. from CSIR-Indian Institute of Chemical Technology, Hyderabad, India, having been skilled with RNAi, liposomal drug delivery, preclinical cell and animal studies. He pursued post-doctoral research at College of Pharmacy, Health Science Center, Texas A & M University and was involved in another postdoctoral research at Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, California. In 2015, he worked in Harvard-MIT Health Sciences & Technology as a visiting scientist. He has substantial experience in nanotechnology-based formulation development and successfully served various Indian organizations to develop pharmaceuticals and nutraceutical products. He is an inventor in many US patents and an author in many peer-reviewed articles published in various international journals of repute. Dr. Mukherjee is currently serving as Principal Scientist, R&D at Esperer Onco Nutrition (EON) Pvt. Ltd. and heads the Hyderabad R&D center of the organization.
Employment
-
Esperer Onco Nutrition Principal Scientist2020 - Present
-
Aavishkar Oral Strip Pvt Ltd Senior Manager2019 - Present
-
John Wayne Cancer Institute Postdoctoral Research Associate2018 - Present
-
Texas A&M University College Station Postdoctoral research associate2017 - 2018
-
Invictus Oncology Pvt Ltd Senior Associate Scientist2014 - 2017
Education
- 2007 - 2014
Projects & Funding
Projects & funding information is unavailable.
Publications (23)
- Lung cancer immunotherapy: progress, pitfalls, and promises Save
- Communication in non-communicable diseases (NCDs) and role of immunomodulatory nutraceuticals in their management Save
- EON Therapy Ameliorates Cachexia and Quality of Life in Cancer Patients Save
- Organoids and Commercialization Save
- Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy Save
- Managing Cachexia and Improving Quality of Life in Cancer Patients Using Novel Nutritional Supplements: A PAN India Study Save
- Nanotechnology Application and Intellectual Property Right Prospects of Mammalian Cell Culture Save
- Bioinspired nanoparticles-based drug delivery systems for cancer theranostics Save
- Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy Save
- Advances in the Fabrication of Scaffold and 3D Printing of Biomimetic Bone Graft. Save
- Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics Save
- Designing Stimuli-Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment Save
- Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics Save
- Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer Save
- Biosynthesized Gold and Silver Nanoparticles in Cancer Theranostics Save
- Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics Save
- Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer. Save
- Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Save
- Antibody drug conjugates: Progress, pitfalls, and promises. Save
- Supramolecular combinatorial Therapeutics. Save